Yes, I agree NSB have protocols and a plan well in place. One plan is presumably to show that regenerated optic nerves actually improve vision. You can rewire a house, but if the connections are mixed up then switching on the lights may not work.
ACW have found that 10mg of their drug did not improve cognition, but that 20mg did. That's scarcely a rehashed trial! Correct dosage is critical.
The continuation of Phase 1 means: "XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalationstudy to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers." If that's not a plan, and a scientifically valid one, then what is? So they do know where they are headed next.
I don't see why we should treat these two companies in the same way as we support our own footie team.
NSB Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
